Boule Diagnostics AB (OSTO:BOUL)
kr 3.8 -0.010 (-0.26%) Market Cap: 147.57 Mil Enterprise Value: 351.07 Mil PE Ratio: 0 PB Ratio: 0.86 GF Score: 47/100

Q2 2025 Boule Diagnostics AB Earnings Call Transcript

Jul 18, 2025 / 08:00AM GMT
Release Date Price: kr6.74 (-34.56%)

Key Points

Positve
  • Instrument unit sales grew 17% year over year, reflecting a strategic focus on growing the install base.
  • 5-part instrument sales more than doubled, indicating strong market demand for this technology.
  • Operating expenses were reduced by 47% due to restructuring initiatives, improving cost efficiency.
  • Positive operating cash flow of 2.9 million SEK was achieved, marking a critical milestone.
  • Strengthened executive leadership team with expertise in R&D and project execution to support strategic transformation.
Negative
  • Organic sales declined by 3.3% compared to the previous year.
  • Gross margin declined to 38.7% from 43.1% due to a lower average selling price and product mix.
  • Consumable sales were 12% below last year, largely due to delayed payments and shipments.
  • Operating margin decreased to 4.5% from 7.2% last year, impacted by lower sales and gross margin.
  • Geopolitical instability and a weakening US dollar negatively affected financial performance.
Holger Lembrer
Boule Diagnostics AB - Chief Financial Officer

Good Morning everybody and welcome to the 2nd quarter's earnings call for Boor Diagnostics. I'm Jorge Lambe, CFO for Boo Diagnostics, and with me I have our CEO Torin Nielsen. After our presentation, we will open up for questions. Please also feel free to type questions in the chat field. With that, I'm handing over to you, Torman.

Torben Nielsen
Boule Diagnostics AB - Chief Executive Officer

Thank you, Volger and good morning and welcome to all of you joining this C2 earnings call.

Let's begin by looking at the highlights of the quarter.

The 2nd quarter of the year saw the continued effects of the geopolitical instability with longer than usual supply chain lead times.

Delayed payments from key customers due to continuing bank restrictions.

An unfavorable effects development from a weakening US dollar.

22 was overall and relatively speaking, a stable quarter.

With a 3.3% organic decline compared to last year.

Instrument unit

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot